Cyclacel Pharmaceuticals Profit Margin

Cyclacel Pharmaceuticals (CYCC) currently reports a profit margin of -2.14% as of March 2026. That compares with 87.33% in the prior-year period — down 102.5% year over year. That is below the Healthcare sector average of 15.58%. Use the charts on this page to explore Cyclacel Pharmaceuticals's profit margin history and peer comparisons.

Cyclacel Pharmaceuticals's profit margin decreased from 87.33% to -2.14% — a 102.5% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cyclacel Pharmaceuticals's profit margin of -2.14% is lower than the Healthcare sector average of 15.58%. That is roughly 1473.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Cyclacel Pharmaceuticals's current -2.14% should be judged against Healthcare norms (sector average: 15.58%) and against CYCC's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -2.14%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.58%. From there, open related valuation or income-statement pages for Cyclacel Pharmaceuticals, and consider following CYCC for alerts when major investors trade the stock.